TIPRL

Across TCGA pan-cancer cohorts, TIPRL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TIPRL data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TIPRL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TIPRL expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where TIPRL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.541	0.244	.001	30	view →
HNSC	DFS	Quartile	II,III,IV	0.864	0.672	.016	10	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	9	view →
UCEC	DFS	Median	All	0.927	0.787	.021	4	view →
LSCC	DFS	Quartile	All	0.626	0.812	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TIPRL–PDAC (OS)

Open the PDAC breakdown →